Objective: To investigate the relationship between glucose target time in range (TIR) and liver fibrosis in patients with type 2 diabetes mellitus and metabolic associated fatty liver disease. Methods: From July 2020 to November 2020, 205 patients with type 2 diabetes (T2DM) and metabolic-associated fatty liver disease (MAFLD) who were hospitalized in the department of endocrinology of our hospital were collected. Patients were divided into a non-hepatic fibrosis group (LSM <8.0 kPa) and a liver fibrosis group (LSM ≥8.0 kPa) according to the liver stiffness measurement (LSM) measured by transient elastography. We collected the patients’ medical history, detected bio-chemical data such as blood glucose, blood lipids, liver function, glycosylated hemoglobin, and caculated the body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) and glucose time in range. Using two independent samples t-test and χ2-test to compare the general statistics between the two groups, and Pearson linear correlation analysis was used to compare the correlation between the variables and the single-factor and multi-factor Logistic regression models were utilized to analyze affecting factors. Results: Compared with the non-hepatic fibrosis group, the BMI, triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and HOMA-IR of the liver fibrosis group were higher and its TIR level was lower than that of the non-hepatic fibrosis group (P<0.05). The degree of liver fibrosis was positively related to the patient’s BMI, TG, ALT, AST and HOMA-IR levels (P<0.05) but negatively related to the TIR level (P<0.001). BMI, TG, HOMA-IR and TIR were independent risk factors for liver fibrosis (P<0.05). Conclusion: The lower TIR in patients with type 2 diabetes combined with metabolic associated fatty liver disease, the greater the risk of liver fibrosis.